RxDoctor Payments Data

Ketan Gala, MD

Advanced Heart Failure and Transplant Cardiology · Cherry Hill, NJNPI 1932381035

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (44.4%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Abbott at 43.6% of the total.

$18,010in general payments, 2019–2025

Across 220 payments — averaging $81.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$8K
  • Bridgebio Pharma, Inc.$3K
  • AstraZeneca$2K
  • Impulse Dynamics (USA) Inc.$2K
  • Bayer$854
  • Abiomed$576
  • plus $2K from 14 others

What the payments were for

  • Consulting fees$3,19518%
  • Speaking & faculty fees$2,05011%
  • Travel & lodging$4,42525%
  • Food & beverage$7,99444%
  • Education$3462%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,010 in reported general payments places this provider in the 65th percentile of 21 advanced heart failure and transplant cardiology providers in New Jersey.

See all advanced heart failure and transplant cardiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$113,970
Medicare patients
206
Services billed
2,215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis19$454,436
OpsumitMacitentan30$365,967
EntrestoSacubitril/Valsartan124$137,994
CamzyosMavacamten16$132,115
FarxigaDapagliflozin Propanediol135$126,446
EliquisApixaban86$87,451
VerquvoVericiguat50$44,513
JardianceEmpagliflozin30$39,594
Ambrisentan23$17,091
Sildenafil Citrate19$4,690
Torsemide111$3,026
Bumetanide19$2,128
Metoprolol Succinate75$1,176
Valsartan36$1,056
Tadalafil13$718

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$110$541,886105 claims
Actelion Pharmaceuticals US, Inc.Opsumit$376$365,96730 claims
NovartisEntresto$115$137,994124 claims
E.r. Squibb & Sons, L.L.C.Camzyos$14$132,11516 claims
AstraZenecaFarxiga$2,397$126,446135 claims
MerckVerquvo$230$44,51350 claims
Boehringer IngelheimJardiance$89$39,59430 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 21 advanced heart failure and transplant cardiology providers in New Jersey.

Other advanced heart failure and transplant cardiology in Cherry Hill

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →